Where obstructive sleep apnea treatment is heading
Obstructive sleep apnea · Updated Nov 12, 2026
CPAP works but many people cannot stay on it. A weight-loss injection is now approved for people with obesity, and the first pill is under FDA review. More injections and pills are in late trials.
- 470studies open or running
- 23of them in phase 3
- 3,242papers published this year
- 127NIH-funded projects
-
Now
Nov 2026
A weight-loss injection is approvedHappened 25.3 vs 5.3 fewer pauses an hour
Tirzepatide is approved for adults with obesity and moderate to severe sleep apnea.
25.3 vs 5.3: fewer breathing pauses an hour, tirzepatide vs placebo.
First pill worked in phase 3Happened 44.1% vs 17.6% fewer pauses, pill vs placebo
AD109, taken at bedtime, reduced breathing pauses in two large trials and is under FDA review.
44.1% vs 17.6%: reduction in breathing pauses, AD109 vs placebo.
-
6 months
by May 2027
FDA decision on the first pillLikely 44.1% vs 17.6% fewer pauses, pill vs placebo
The decision on AD109 is due by February 28, 2027.
44.1% vs 17.6%: reduction in breathing pauses, AD109 vs placebo.
More weight-loss injections reportPossible
Phase 3 trials of a newer injection in China reach their completion dates in December 2026.
-
12 months
by Nov 2027
Monthly injection resultsPossible
MariTide, given once a month, in two 250-person trials finishing in August 2027.
A second pill combinationPossible
Dronabinol plus acetazolamide in 120 people finishes in April 2027.
-
3 years
by late 2029
Several injections to choose fromPossible 25.3 vs 5.3 fewer pauses an hour, tirzepatide
Eloralintide and a monthly Pfizer injection finish phase 3 in 2028.
25.3 vs 5.3: fewer breathing pauses an hour with tirzepatide, the first of these drugs.
Injection compared directly with CPAPLong shot
An Australian trial plans to compare tirzepatide head to head with CPAP. It had not opened when last updated.
Does treating apnea protect memory?Possible
An NIH-funded trial tests whether successful treatment changes memory and Alzheimer's markers in older adults.
-
5 years
by late 2031
Treatment matched to the causeLong shot
Apnea has different causes in different people: anatomy, muscle response, waking too easily. Trials are testing drugs chosen by cause.
The research paths
Weight-loss injections
25.3 vs 5.3 fewer pauses an hourDetails and 4 trialsHide
After tirzepatide, most new obesity drugs are being tested in sleep apnea, including monthly injections.
WatchWhether people can stop CPAP, not only reduce pauses.
Pills that keep the airway open
44.1% vs 17.6% fewer pauses, pill vs placeboDetails and 2 trialsHide
Drugs that keep throat muscles active or steady breathing control during sleep. They do not depend on weight.
WatchThe FDA decision in February 2027.
Matching treatment to the cause
Details and 2 trialsHide
Testing whether measuring why a person's airway closes can pick the treatment that will work for them.
WatchSimple tests that work outside a sleep lab.
Borrowed from other conditions
From Diabetes and obesity
Tirzepatide
25.3 vs 5.3 fewer pauses an hour
Approved
A weekly injection for weight loss, now approved for sleep apnea in adults with obesity.
From ADHD and bladder medicines
Atomoxetine and aroxybutynin
44.1% vs 17.6% fewer pauses, pill vs placebo
Under FDA review
An ADHD drug paired with a relative of a bladder drug. Together they keep throat muscles working during sleep.
From Chemotherapy nausea
Dronabinol
Phase 2
A synthetic cannabinoid, combined with acetazolamide, a drug used for altitude sickness.
From Insomnia
Eszopiclone
Phase 3
A sleeping pill, tested in people whose apnea is worsened by waking too easily.
Open to join now
-
Sleep apnea with obesity
Eloralintide injection (ENLIGHTEN-3)
Locations and eligibility → -
Sleep apnea with obesity
Berobenatide monthly injection
Locations and eligibility → -
Sleep apnea
Dronabinol plus acetazolamide pill
Locations and eligibility → -
Sleep apnea, Yale
Eszopiclone with CPAP (CALM-OSA)
Locations and eligibility →
See every recruiting sleep apnea trial →
When the large trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
Knowledge on the way
Not treatments yet: detection, causes and how care is delivered. Mostly NIH-funded.
- AreaQuestionFunded throughNews likely
- Risk Does treating sleep apnea protect memory in older adults?California Pacific Medical Center · NIH Funded through Aug 2028 News likely 2028–2029
- Care Treating sleep apnea after a stroke (Sleep SMART)University of Michigan · NIH Funded through Apr 2027 News likely 2027
- Care Oxygen therapy for children and teens with sleep apneaCincinnati Children's · NIH Funded through Aug 2027 News likely 2027–2028
- Causes Predicting who is harmed by sleep apnea and who responds to treatmentUniversity of Pennsylvania · NIH Funded through Jun 2028 News likely 2027–2028
What just happened
FDA accepts application for the first sleep apnea pill
Decision on AD109 due February 28, 2027.
AD109 phase 3 results published
Breathing pauses down 44.1% vs 17.6% with placebo.
Tirzepatide trials reported
25 to 29 fewer breathing pauses an hour.
Standard treatment today
- Moderate to severe apneaCPAP, a mask and machine that hold the airway open during sleep.
- With obesityWeight loss, including tirzepatide, which is approved for this.
- CPAP not toleratedA fitted mouthpiece that moves the jaw forward, an implanted nerve stimulator, or surgery for selected people.
How to read this page, and sourcesHow to read this page, and sources
- Fewer breathing pauses is a measurement from a sleep study. Benefits for heart health and daytime function need longer trials.
- The injections were tested in people with obesity. They are not a treatment for apnea from other causes.
- Completion dates are what each trial registered. Results usually follow 3 to 12 months later.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See sleep apnea trials recruiting now →